share_log

Avenue Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Fortress Biotech, Inc.(8.0%)

Avenue Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Fortress Biotech, Inc.(8.0%)

Avenue Therapeutics | SC 13D/A：超過5%持股股東披露文件(修正)-Fortress Biotech, Inc.(8.0%)
美股sec公告 ·  04/18 04:11
牛牛AI助理已提取核心訊息
On April 16, 2024, Fortress Biotech, Inc. filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing the acquisition of additional shares in Avenue Therapeutics, Inc. The filing, known as Amendment No. 4, indicates that Fortress Biotech now beneficially owns 3,564,059 shares of Avenue Therapeutics' common stock, which represents approximately 8.0% of the company's outstanding common stock. This ownership includes 250,000 shares of Class A preferred stock, convertible into 16,666 shares of common stock, and 22,222 shares issuable under warrants. The acquisition of 413,507 shares of common stock was part of an Offering Equity Grant resulting from a transaction completed in the first fiscal quarter of 2024. The filing also outlines the rights and conversion details of the Class A preferred stock and the terms of the warrants held by Fortress Biotech's executives. The Amendment No. 4 does not propose any changes to the company's management, structure, or business operations.
On April 16, 2024, Fortress Biotech, Inc. filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing the acquisition of additional shares in Avenue Therapeutics, Inc. The filing, known as Amendment No. 4, indicates that Fortress Biotech now beneficially owns 3,564,059 shares of Avenue Therapeutics' common stock, which represents approximately 8.0% of the company's outstanding common stock. This ownership includes 250,000 shares of Class A preferred stock, convertible into 16,666 shares of common stock, and 22,222 shares issuable under warrants. The acquisition of 413,507 shares of common stock was part of an Offering Equity Grant resulting from a transaction completed in the first fiscal quarter of 2024. The filing also outlines the rights and conversion details of the Class A preferred stock and the terms of the warrants held by Fortress Biotech's executives. The Amendment No. 4 does not propose any changes to the company's management, structure, or business operations.
2024年4月16日，豐澤生物科技公司向美國證券交易委員會提交了附表13D的修正案，披露了對Avenue Therapeutics, Inc.額外股份的收購。該文件被稱爲第4號修正案，表明豐澤生物科技現在實益擁有Avenue Therapeutics普通股的3564,059股，約佔該公司已發行普通股的8.0％。該所有權包括25萬股A類優先股，可轉換爲16,666股普通股，以及根據認股權證可發行的22,222股股票。413,507股普通股的收購是2024年第一財季完成的交易產生的發行股權補助的一部分。該文件還概述了A類優先股的權利和轉換細節以及豐澤生物科技高管持有的認股權證的條款。第4號修正案沒有提議對公司的管理、結構或業務運營進行任何更改。
2024年4月16日，豐澤生物科技公司向美國證券交易委員會提交了附表13D的修正案，披露了對Avenue Therapeutics, Inc.額外股份的收購。該文件被稱爲第4號修正案，表明豐澤生物科技現在實益擁有Avenue Therapeutics普通股的3564,059股，約佔該公司已發行普通股的8.0％。該所有權包括25萬股A類優先股，可轉換爲16,666股普通股，以及根據認股權證可發行的22,222股股票。413,507股普通股的收購是2024年第一財季完成的交易產生的發行股權補助的一部分。該文件還概述了A類優先股的權利和轉換細節以及豐澤生物科技高管持有的認股權證的條款。第4號修正案沒有提議對公司的管理、結構或業務運營進行任何更改。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。